CTIX Interviews, Potential Catalysts and Past Mile
Post# of 72447
Posted On: 08/11/2016 6:21:32 PM
CTIX Interviews, Potential Catalysts and Past Milestones
Recent Interviews
- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-inter...-bertolino
- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cell...-milestone
- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a...-jorgensen
H2 2016 Potential Catalysts
- B-OM interim data (Phase 2)
- B-UP interim data (Phase 2 POC)
- K top-line data (Phase 1)
- Start of K-ovarian (Phase 2)
- Start of P (Phase 2b)
Past Milestones
Kevetrin
- Orphan drug designation for K-ovarian cancer
http://cellceutix.com/cellceutixs-kevetrin-re...U1TnV.dpbs
- Orphan drug designation for K-pancreatic cancer
http://cellceutix.com/cellceutix-receives-fda...ZiRj0.dpbs
- Orphan drug designation for K-retinoblastoma
http://cellceutix.com/cellceutix-receives-fda...NePSd.dpbs
- Rare pediatric disease designation for K-retinoblastoma
http://cellceutix.com/cellceutix-receives-rar...jI8sG.dpbs
- Positive primary endpoint (Phase 1)
http://cellceutix.com/cellceutix-prepares-pha...Ur7N7.dpbs
Brilacidin
- QIDP designation for B-ABSSSI
http://cellceutix.com/cellceutix-antibiotic-b...vWGbq.dpbs
- Fast track designation for B-OM
http://cellceutix.com/fda-grants-fast-track-d...pFvLG.dpbs
- B-ABSSSI positive top-line & bottom line data (Phase 2b)
http://cellceutix.com/cellceutix-announces-po...LBVb3.dpbs
- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/A...#corresp-1
- MTA extension for testing in implanted devices
http://cellceutix.com/cellceutix-completes-la...iYemt.dpbs
- Formulation stable at room temperature
http://cellceutix.com/cellceutix-announces-br...Zuqak.dpbs
Prurisol
- Positive top-line data (Phase 2a)
http://cellceutix.com/cellceutix-phase-2-tria...e9gTP.dpbs
- Positive primary endpoint (Phase 1)
http://cellceutix.com/cellceutix-anti-psorias...aMllD.dpbs
- 505(b)(2) pathway
http://cellceutix.com/cellceutix-informed-by-...BHEyW.dpbs
Clinical Trials
1. P (Phase 1, completed)
https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1
2. P (Phase 2, completed)
https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=2
3. B-OM (Phase 2, recruiting)
https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
4. B-ABSSSI (Phase 2, completed)
https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=4
5. K (Phase 1, completed)
https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=5
6. B-UP (Phase 2 POC, recruiting)
http://cellceutix.com/cellceutix-receives-upd...5eSu9.dpbs
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product
Pipeline
Recent Interviews
- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-inter...-bertolino
- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cell...-milestone
- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a...-jorgensen
H2 2016 Potential Catalysts
- B-OM interim data (Phase 2)
- B-UP interim data (Phase 2 POC)
- K top-line data (Phase 1)
- Start of K-ovarian (Phase 2)
- Start of P (Phase 2b)
Past Milestones
Kevetrin
- Orphan drug designation for K-ovarian cancer
http://cellceutix.com/cellceutixs-kevetrin-re...U1TnV.dpbs
- Orphan drug designation for K-pancreatic cancer
http://cellceutix.com/cellceutix-receives-fda...ZiRj0.dpbs
- Orphan drug designation for K-retinoblastoma
http://cellceutix.com/cellceutix-receives-fda...NePSd.dpbs
- Rare pediatric disease designation for K-retinoblastoma
http://cellceutix.com/cellceutix-receives-rar...jI8sG.dpbs
- Positive primary endpoint (Phase 1)
http://cellceutix.com/cellceutix-prepares-pha...Ur7N7.dpbs
Brilacidin
- QIDP designation for B-ABSSSI
http://cellceutix.com/cellceutix-antibiotic-b...vWGbq.dpbs
- Fast track designation for B-OM
http://cellceutix.com/fda-grants-fast-track-d...pFvLG.dpbs
- B-ABSSSI positive top-line & bottom line data (Phase 2b)
http://cellceutix.com/cellceutix-announces-po...LBVb3.dpbs
- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/A...#corresp-1
- MTA extension for testing in implanted devices
http://cellceutix.com/cellceutix-completes-la...iYemt.dpbs
- Formulation stable at room temperature
http://cellceutix.com/cellceutix-announces-br...Zuqak.dpbs
Prurisol
- Positive top-line data (Phase 2a)
http://cellceutix.com/cellceutix-phase-2-tria...e9gTP.dpbs
- Positive primary endpoint (Phase 1)
http://cellceutix.com/cellceutix-anti-psorias...aMllD.dpbs
- 505(b)(2) pathway
http://cellceutix.com/cellceutix-informed-by-...BHEyW.dpbs
Clinical Trials
1. P (Phase 1, completed)
https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1
2. P (Phase 2, completed)
https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=2
3. B-OM (Phase 2, recruiting)
https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
4. B-ABSSSI (Phase 2, completed)
https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=4
5. K (Phase 1, completed)
https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=5
6. B-UP (Phase 2 POC, recruiting)
http://cellceutix.com/cellceutix-receives-upd...5eSu9.dpbs
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product
Pipeline
(4)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
